Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CABA

Cabaletta Bio Inc

Apr 10 • 04:00PM ET

3.13

-0.04 -1.26 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE BMRN EDIT TGTX NTLA ALLO SGMO ANIX ADAP

| Held by: VTI VXF IBB IWC DFAS PRFZ AVSC DFMC TMED DFAU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.29	Insider Own	12.43%	Shs Outstand	100.48M	Perf Week	5.74%
Market Cap	348.44M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	0.96%	Shs Float	97.48M	Perf Month	-4.28%
Enterprise Value	241.94M	PEG	-	EPS next Q	-0.39	Inst Own	62.00%	Short Float	20.48%	Perf Quarter	44.24%
Income	-167.86M	P/S	-	EPS this Y	25.55%	Inst Trans	3.15%	Short Ratio	6.52	Perf Half Y	29.88%
Sales	0.00M	P/B	2.81	EPS next Y	3.95%	ROA	-93.45%	Short Interest	19.97M	Perf YTD	42.92%
Book/sh	1.12	P/C	2.61	EPS next 5Y	11.56%	ROE	-126.98%	52W High	3.78 -17.20%	Perf Year	187.16%
Cash/sh	1.20	P/FCF	-	EPS past 3/5Y	-5.18% -7.84%	ROIC	-146.05%	52W Low	1.04 200.96%	Perf 3Y	-61.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.21% 7.92%	Perf 5Y	-70.91%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	1.79%	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.28	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	2.77	EPS Q/Q	35.82%	SMA20	7.28%	Beta	3.37	Target Price	13.12
Payout	-	Debt/Eq	0.24	Sales Q/Q	-	SMA50	6.20%	Rel Volume	0.38	Prev Close	3.17
Employees	156	LT Debt/Eq	0.03	Earnings	Mar 23 BMO	SMA200	34.49%	Avg Volume	3.06M	Price	3.13
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.29% -	Trades		Volume	1,177,864	Change	-1.26%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-25	Resumed	Jefferies	Buy	$14
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line	$15 → $6
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12 → $6
Oct-10-24	Initiated	UBS	Buy	$10
Feb-05-24	Initiated	Jefferies	Buy	$36
Nov-29-23	Initiated	William Blair	Outperform	$38
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$40
Oct-19-23	Initiated	Stifel	Buy	$31
Sep-05-23	Initiated	Citigroup	Buy	$22
Jul-18-23	Initiated	Guggenheim	Buy	$34
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$3 → $16
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$15 → $3
Dec-08-21	Initiated	Wells Fargo	Overweight	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$20
Jun-30-21	Initiated	Mizuho	Buy	$22
Jan-08-21	Initiated	Chardan Capital Markets	Buy	$21
Oct-13-20	Initiated	H.C. Wainwright	Buy	$20
Nov-19-19	Initiated	Morgan Stanley	Overweight	$19
Nov-19-19	Initiated	Evercore ISI	Outperform	$25
Nov-19-19	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-27-26 01:11PM	This Biotech Stock Could Deliver 350% Returns in 12 Months (GuruFocus.com)
Mar-23-26 07:30AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-26 05:46AM	Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference (MarketBeat)
Mar-06-26 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-03-26 09:40AM	Are Medical Stocks Lagging Biodesix (BDSX) This Year? (Zacks)
08:00AM	Loading…
Feb-24-26 08:00AM	Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +13.45%
Feb-18-26 08:34AM	Here's Why Jacob Funds Established a Position in Cabaletta Bio (CABA) (Insider Monkey) +5.74%
Feb-13-26 12:07AM	Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA (MarketBeat)
Feb-12-26 09:40AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? (Zacks) +10.89%
Feb-05-26 08:00AM	Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.17%
Jan-30-26 12:00PM	What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? (Zacks) -6.55%
Jan-27-26 09:40AM	Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-12-26 08:00AM	Cabaletta Bio Announces 2026 Strategic Priorities (GlobeNewswire) +5.24%
07:30AM	IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms (Business Wire)
Nov-10-25 07:30AM	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:40AM	Loading…
Nov-04-25 09:40AM	Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? (Zacks) -10.30%
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December (GlobeNewswire)
Oct-31-25 05:42AM	Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials (Insider Monkey) +46.15%
Oct-27-25 07:00AM	Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 (GlobeNewswire) +12.96%
Oct-14-25 08:00AM	Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant (GlobeNewswire) +16.06%
Oct-09-25 12:00PM	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress (GlobeNewswire) +18.26%
Aug-27-25 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-11-25 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's Why (Zacks)
Aug-07-25 07:30AM	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 09:54AM	Cabaletta Bio Announces Pricing of Public Offering of Securities (GlobeNewswire) -25.53%
06:15AM	Cabaletta Bio Announces Proposed Public Offering of Securities (GlobeNewswire)
06:00AM	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress (GlobeNewswire)
May-29-25 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-15-25 07:00AM	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts (GlobeNewswire) +39.23%
12:16PM	Loading…
Apr-01-25 12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks) -15.52%
Mar-31-25 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.65%
Mar-19-25 07:00AM	Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform (Business Wire) +6.59%
Feb-26-25 08:00AM	Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 10:21AM	UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire) -14.02%
07:00AM	Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire)
Feb-11-25 08:00AM	Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February (GlobeNewswire)
Jan-29-25 08:00AM	Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 (GlobeNewswire)
Nov-26-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in December (GlobeNewswire) +5.68%
Nov-18-24 07:00AM	Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 (GlobeNewswire) -10.89%
Nov-14-24 07:00AM	Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.74%
Nov-06-24 08:00AM	Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire) +10.71%
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings (GuruFocus.com)
Sep-25-24 04:30PM	Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:32AM	Several Headwinds Dragged Cabaletta Bio (CABA) in Q2 (Insider Monkey) +20.65%
Aug-08-24 07:00AM	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -34.37%
Jul-08-24 07:01PM	Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now? (Insider Monkey) +7.23%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum (GlobeNewswire) -5.38%
Jun-14-24 02:00AM	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201 (GlobeNewswire) -15.13%
May-29-24 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -5.81%
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-15-24 11:54AM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 (InvestorPlace) +13.00%
07:00AM	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-23-24 05:31AM	Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway (GuruFocus.com)
Mar-21-24 01:53PM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:00AM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis (GlobeNewswire)
Mar-08-24 08:50AM	Jim Cramer's 10 Latest Stock Picks This Week (Insider Monkey)
Feb-27-24 10:11AM	Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 (Insider Monkey)
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-01-24 04:30PM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis (GlobeNewswire) +7.05%
Jan-31-24 08:00AM	Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:00AM	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis (GlobeNewswire) +8.70%
Jan-02-24 08:00AM	Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:49PM	Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally (TipRanks) +7.14%
Nov-28-23 04:30PM	Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -26.79%
Nov-09-23 08:10AM	Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
07:00AM	Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:15AM	Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabalettas CD19-CAR T Cell Therapy on Cellares Cell Shuttle Platform (Business Wire)
07:00AM	Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis (GlobeNewswire)
Oct-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November (GlobeNewswire) +7.50%
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks) +5.70%
Oct-02-23 09:14AM	QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software (Zacks)
07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 (GlobeNewswire)
Oct-01-23 11:00AM	Top Stocks for October 2023 (Investopedia)
Sep-25-23 08:50AM	What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing' (Zacks)
Sep-19-23 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire) -6.92%
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -5.93%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:55AM	Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade (Zacks)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-23 10:13AM	Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment (American City Business Journals)
Aug-23-23 08:50AM	Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why (Zacks)
Aug-22-23 08:00AM	Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 (GlobeNewswire)
Aug-15-23 01:46PM	Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect? (Zacks)
Aug-10-23 07:00AM	Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia) -7.27%
Jul-24-23 08:00AM	Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors (GlobeNewswire) -6.68%
Jul-18-23 02:58PM	Why Shares of Cabaletta Bio Are Up Tuesday (Motley Fool) +11.93%
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire) -5.26%
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
May-31-23 08:00AM	Cabaletta Bio to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:33AM	Institutional investors in Cabaletta Bio, Inc. (NASDAQ:CABA) lost 18% last week but have reaped the benefits of longer-term growth (Simply Wall St.)
May-22-23 04:30PM	Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
May-17-23 10:16PM	Cabaletta Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.83%

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chang David J.	Chief Medical Officer	Jan 21 '26	Buy	2.26	8,800	19,888	8,800	Jan 21 06:56 PM
Binder Gwendolyn	President, Science & Tech.	Jan 21 '26	Buy	2.19	11,312	24,763	31,312	Jan 21 06:56 PM
Tomasello Shawn	Director	Jan 21 '26	Buy	2.21	22,725	50,322	22,725	Jan 21 06:55 PM
Gavel Steve	Chief Commercial Officer	Jan 21 '26	Buy	2.27	22,170	50,215	22,170	Jan 21 06:55 PM
Bollard Catherine	Director	Jan 21 '26	Buy	2.27	4,405	9,982	5,405	Jan 21 06:54 PM
Nichtberger Steven	President & CEO	Jan 21 '26	Buy	2.24	45,000	100,778	1,031,483	Jan 21 06:54 PM
Simon Mark	Director	Jan 21 '26	Buy	2.28	11,061	25,261	147,205	Jan 21 06:53 PM
Gerard Michael	General Counsel	Jan 21 '26	Buy	2.27	6,600	14,979	6,600	Jan 21 06:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CABA

Cabaletta Bio Inc

Upgrade your Finviz experience